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Abstract
The active extrusion of cytotoxic compounds from the cell by multidrug transporters is one of the major causes of failure
of chemotherapeutic treatment of tumor cells and of infections by pathogenic microorganisms. A multidrug transporter in
Lactococcus lactis, LmrA, is a member of the ATP-binding cassette (ABC) superfamily and a bacterial homolog of the
human multidrug resistance P-glycoprotein. Another multidrug transporter in L. lactis, LmrP, belongs to the major
facilitator superfamily, and is one example of a rapidly expanding group of secondary multidrug transporters in
microorganisms. Thus, LmrA and LmrP are transport proteins with very different protein structures, which use different
mechanisms of energy coupling to transport drugs out of the cell. Surprisingly, both proteins have overlapping specificities
for drugs, are inhibited by the same set of modulators, and transport drugs via a similar transport mechanism. The structure-
function relationships that dictate drug recognition and transport by LmrP and LmrA represent an intriguing area of
research. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
The nutritive and therapeutic treatment of farm
animals with antibiotics, amounting to half of the
world’s antibiotic output, has selected for drug-resis-
tant microorganisms that contaminate the food pro-
duced [1]. Likewise, the selection of drug-resistant
pathogenic microorganisms in hospitalized patients
with serious infections such as pneumonia, urinary
tract infections, skin infections, and bacteremia has
generally been ascribed to the widespread use of anti-
microbial agents [2]. Besides bacteria, parasitic pro-
tozoa are responsible for some of the most devastat-
ing and prevalent diseases of humans and domestic
animals, such as malaria (Plasmodium spp.) and
toxoplasmosis (Toxoplasma spp.) [3].
Microorganisms can eliminate the drug target in
the cell through the alteration or replacement of mol-
ecules that are normally bound by the antibiotic [4].
Alternatively, microorganisms can reduce the intra-
cellular concentration of drugs by: (i) synthesizing
enzymes that degrade antibiotics or that chemically
modify, and so inactivate, the drugs [5], (ii) eliminat-
ing entry ports for hydrophilic drugs, such as outer
membrane porins in Gram-negative bacteria [6], and
(iii) manufacturing drug e¥ux systems that export
lipophilic drugs before these compounds have the
chance to ¢nd their cellular targets [7,8]. Some of
these drug e¥ux systems are fairly speci¢c for a giv-
en drug or class of drugs, but the so-called multidrug
transporters have speci¢city for compounds with
very di¡erent chemical structures and cellular targets.
Multidrug transporters can be ampli¢ed in drug-re-
sistant pathogenic microorganisms, and can shift
their drug pro¢les, making them a menace to drug
treatment.
2. Multidrug transporters LmrA and LmrP
Lactococcus lactis has developed fascinating anti-
biotic resistance mechanisms. A membrane protein,
LmrA, belongs to the ATP-binding cassette (ABC)
superfamily and is driven by ATP-hydrolysis. LmrA
contains an N-terminal membrane domain with six
membrane-spanning segments followed by the ABC
domain [9]. LmrA is homologous to prokaryotic
ABC transporters in Bacillus subtilis, Staphylococcus
aureus, Escherichia coli, Helicobacter pylori, Haemo-
philus in£uenzae, and Mycoplasma genitalium [10]
and to the hop resistance protein HorA in the
beer-spoilage bacterium Lactobacillus brevis [11].
LmrA is also homologous to eukaryotic ABC trans-
porters, and is a half-molecule version of the human
multidrug resistance P-glycoprotein which is a cause
of multidrug resistance of tumor cells during chemo-
therapy [12]. Recent studies of the expression of co-
valently linked dimers of LmrA in L. lactis suggests
that, by analogy with P-glycoprotein, LmrA is trans-
port active as a homodimer [13]. Another multidrug
transporter in L. lactis, LmrP, mediates drug extru-
sion by a proton motive force-driven, electrogenic
proton/drug exchange reaction [14]. LmrP contains
12 membrane-spanning segments which are con-
nected by hydrophilic loops protruding into the cy-
toplasmic and extracellular space, and is a member
of the major facilitator superfamily [15]. LmrP is
homologous to various multidrug transporters in
pathogenic bacteria and to the mammalian organic
cation transporter OCT1 in kidney epithelial cells
[8].
3. From cells to proteoliposomes
LmrA and LmrP were initially characterized in a
number of mutants of L. lactis MG1363 which were
isolated on the basis of resistance to high concentra-
tions of ethidium, daunomycin, and rhodamine 6G,
and which showed an increased rate of energy-de-
pendent ethidium and daunomycin e¥ux compared
to the wild-type [16]. Subsequently, the genes encod-
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ing these transport proteins were identi¢ed and ex-
pressed in E. coli and L. lactis. Gene inactivation
studies in L. lactis have established that ATP-de-
pendent drug extrusion via LmrA still occurs in a
L. lactis lmrP strain [15]. Methods have been devel-
oped to routinely overexpress histidine-tagged LmrA
and LmrP in L. lactis, for LmrA up to levels of 30%
of total membrane protein [17,18]. For this expres-
sion, a novel protein-expression system for cytotoxic
proteins is used which is based on the nisin-inducible
nisA promoter [19]. LmrA and LmrP were e⁄ciently
solubilized with dodecyl maltoside (DDM), puri¢ed
by Ni-a⁄nity chromatography, and reconstituted in
DDM-destabilized preformed liposomes prepared
from E. coli phospholipids and egg phosphatidylcho-
line. Interestingly, the inhibition of the activity of
LmrP by detergents restricted the range of com-
pounds that could be used for solubilization and re-
constitution of the protein, because low concentra-
tions of detergent are retained in proteoliposomes
[17]. Currently, structural and functional properties
of LmrA and LmrP are studied in whole cells, plas-
ma membrane vesicles, and proteoliposomes contain-
ing the puri¢ed and reconstituted proteins.
4. Drug speci¢city
The drug speci¢city is one of the most intriguing
aspects of LmA and LmrP. The number of com-
pounds that are recognized by these proteins is
vast. To compare the pharmacological properties of
bacterial LmrA with those of its human homolog
P-glycoprotein, LmrA was functionally expressed in
human lung ¢broblast cells and insect cells which
previously had been used for the characterization
of P-glycoprotein [20]. Lung ¢broblast cells express-
ing LmrA protein showed a 10- to 60-fold increased
resistance to a variety of natural product drugs and
synthetic chemotherapeutic drugs which are typical
substrates of P-glycoprotein [21]: (i) anthracyclines
such as daunomycin and doxorubicin; (ii) vinca-al-
kaloids such as vinblastine and vincristine; and (iii)
cytotoxic agents such as ethidium bromide, rhod-
amine 6G and 123, and colchicine. P-glycoprotein
function can be inhibited by a large group of struc-
turally unrelated modulators [21]. All of these mod-
ulators tested also reversed drug resistance generated
by expression of LmrA in lung ¢broblast cells: (i)
calcium channel blockers such as verapamil and its
Table 1
Binding and transport of clinically relevant antibiotics by LmrP
Group Antibiotic Binding to LmrP Transport by LmrP
Aminoglycosides gentamycin 3 3
kanamycin 3 3
L-Lactams meropenem 3 3
Cephalosporins ceftazidime n.t.a 3
Lincosamides clindamycin + +






Penicillins ampicillin 3 3
Quinolones cipro£oxacin n.t. 3
o£oxacin n.t. 3
Streptogramins dalfopristin + +
quinupristin + 3
Tetracyclines tetracycline n.t. +
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analog CP100^356; (ii) 1,4-dihydropyridines such as
nicardipine; (iii) indolizine sulfones such as
SR33557; (iv) antimalarials such as quinine and qui-
nidine; (v) immunosuppressants such as cyclosporin
A; (vi) the Rauwol¢a alkaloid reserpine; and (vii) the
phenylalkylamine verapamil. Thus, the drug and
modulator speci¢city of LmrA is very similar to
that of P-glycoprotein. Interestingly, all compounds
mentioned above also interact with the secondary
multidrug transporter LmrP. In addition, LmrA
and LmrP are able to transport antibiotics. Recently,
this phenomenon has been studied in detail for LmrP
(Table 1). From toxicity assays in whole cells of L.
lactis and E. coli, and transport studies in membrane
vesicles and proteoliposomes it was concluded that
LmrP mediates the transport of various members of
the lincosamides, macrolides, streptogramins, and
tetracyclins [22]. These observations demonstrate
the important role that multidrug transporters play
in microbial antibiotic resistance.
5. Transport models
Several transport models have been postulated for
LmrP, LmrA and P-glycoprotein pump function to
explain the broad speci¢city for chemically unrelated
compounds. Drug translocation may involve sub-
strate transport from the cytoplasm to the exterior
(conventional transport hypothesis [23]) which would
require £exibility of an ‘enzyme-like’ drug recogni-
tion site. However, a property common to most
LmrP, LmrA and P-glycoprotein substrates is their
ability to intercalate between the phospholipids of
biological membranes. This notion has led to the
suggestion that these transporters recognize drugs
within the membrane (vacuum cleaner and £ippase
hypotheses [14,24^26]). Drug recognition within the
membrane is supported by a number of observa-
tions: (i) photo-a⁄nity analogs of P-glycoprotein
substrates label P-glycoprotein predominantly in or
near the transmembrane helices 4^6, and 11^12 [27^
29], (ii) point mutations resulting in the alteration in
drug speci¢city of P-glycoprotein are frequently
found in transmembrane helices [12], (iii) acetoxy-
methyl esters of several £uorescent probes accumu-
late less in P-glycoprotein or LmrA-expressing cells,
despite the fact that the ester moieties are rapidly
cleaved by intracellular esterases and the resulting
carboxylates are not substrates for P-glycoprotein
and LmrA [26,30], (iv) the kinetics of ATP-depend-
ent transport of Hoechst 33342 by P-glycoprotein
and LmrP, and of TMA-DPH by LmrA and LmrP
in membrane vesicles is consistent with transport of
the compounds from the inner, but not from the
outer lea£et of the lipid bilayer [14,26,31,32]. This
transport mechanism is likely to be a more general
mechanism for membrane transporters with hydro-
phobic substrates. The human MDR2 gene-encoded
P-glycoprotein transports phosphatidylcholine from
the cytoplasmic lea£et of the bile canicular mem-
brane of hepatocytes into the bile [33,34]. In addi-
tion, the E. coli hemolysine transporter HlyB most
likely binds the transport signal sequence of hemoly-
sine, when the signal sequence forms an amphiphilic
helix that binds to the cytoplasmic lea£et of the plas-
ma membrane [35,36]. Thus, a main determinant of
speci¢city for multidrug transporters will be the abil-
ity of drugs to be intercalated into the lipid bilayer.
The subsequent interactions between drug molecules
and drug binding sites on the transport proteins will
be the second determinant of drug speci¢city.
6. Multiple drug binding sites
There is increasing evidence for the presence of
more than one drug binding site on LmrP and
LmrA. For LmrP, transport studies in membrane
vesicles of L. lactis suggest that some drugs inhibit
LmrP-mediated Hoechst 33342 transport through
competition with Hoechst 33342 for binding to the
same drug binding site on LmrP, whereas other
drugs inhibit LmrP-mediated Hoechst 33342 trans-
port non-competitively, through binding to a drug
binding site di¡erent from the Hoechst 33342 binding
site [37]. Similar observations have been reported for
the staphylococcal proton motive force-dependent
multidrug export protein QacA [38]. Competition
studies showed that the QacA-mediated export of
ethidium is competitively inhibited by monovalent
cations, and non-competitively inhibited by divalent
cations, which suggests that monovalent and divalent
cations bind at separate sites on the QacA protein.
Thus, LmrP and QacA each contain at least two
distinct drug binding sites. Recently, a 3-dimensional
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(3D) structure analysis of the B. subtilis transcrip-
tional regulator BmrR [39], and site-directed muta-
genesis studies on the E. coli multidrug resistance
protein MdfA [40] have revealed that a negatively
charged glutamate residue in a hydrophobic environ-
ment plays a key role in the cation selectivity of these
proteins. Similarly, the three negatively charged res-
idues in putative transmembrane segments of LmrP
(D142 in TM5, E327 in TM10, and E388 in TM12)
may play a role in the binding of cationic drugs by
LmrP. For LmrA expressed in plasma membranes of
Spodoptera frugiperda insect cells [20] and P-glyco-
protein expressed in plasma membranes of Chinese
hamster ovary B30 cells [41^43], kinetic analysis of
drug dissociation revealed the presence of two non-
identical, allosterically linked drug binding sites in
both proteins.
7. Concluding remarks
Multidrug resistance in eukaryotic and prokaryotic
cells is an increasingly complex clinical and public
health problem. Prevention and control strategies
will require the application of epidemiological and
behavioral approaches, as well as research technolo-
gies aimed at the basic mechanisms of drug resist-
ance. Understanding the molecular basis of drug rec-
ognition and transport by multidrug transporters will
ultimately require the elucidation of their structures
to high resolution. As yet there is no structural in-
formation of su⁄cient detail available. A recent re-
port on the structure of P-glycoprotein at 2.5 nm
resolution showed a monomeric molecule with dis-
crete domains [44], giving a promising basis for the
future. For LmrA and LmrP, milligram quantities of
highly puri¢ed protein can be obtained rather easily.
These results give us a very good starting point for
protein crystallization procedures.
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